Core Outcome Set for GROwth restriction: DeVeloping Endpoints (COSGROVE)

Patricia Healy, Sanne Gordijn, Wessel Ganzevoort, Irene Beune, Ahmet Baschat, Asma Khalil, Louise Kenny, Frank Bloomfield, Mandy Daly, Aris Papageorghiou, Declan Devane

Research output: Contribution to journalArticle

Abstract

Background: Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) - one for prevention and the other for treatment of FGR. Methods: We will review the literature to identify previously reported outcomes. An international panel of relevant stakeholders who have experience of FGR (parent or carer of a baby that was growth restricted, health professional involved in the care of mothers and babies affected by FGR, a person with expertise in FGR research) will rate the importance of each of those outcomes in a series of three sequential online rounds of a Delphi study. Participants will be able to add items to the proposed list in round 1. A final face-to-face consensus meeting will be held with representatives of each stakeholder group at which a final list of outcomes for inclusion in the COS will be agreed. Discussion: The development of COSs in FGR will ensure the collection and reporting of a minimum dataset agreed by stakeholder consensus and will reduce inconsistencies in the reporting of outcomes across relevant trials. Such standardisation in the reporting of outcomes will improve synthesis of evidence and generalisability of knowledge in the future by reducing heterogeneity in outcomes between trials and thus improve the results of systematic reviews and meta-analyses. Ultimately, we hope that the COSs will lead to an improvement in the quality of evidence-based clinical practice, enhance patient care, and improve the quality and consistency of research.

Original languageEnglish (US)
Article number451
JournalTrials
Volume19
Issue number1
DOIs
StatePublished - Aug 22 2018

Fingerprint

Fetal Development
Growth
Consensus
Fetus
Delphi Technique
Stillbirth
Evidence-Based Practice
Health
Quality Improvement
Research
Caregivers
Meta-Analysis
Patient Care
Cardiovascular Diseases
Mothers
Morbidity

Keywords

  • Core outcome sets
  • Delphi
  • Foetal growth restriction
  • Methodology
  • Pregnancy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Healy, P., Gordijn, S., Ganzevoort, W., Beune, I., Baschat, A., Khalil, A., ... Devane, D. (2018). Core Outcome Set for GROwth restriction: DeVeloping Endpoints (COSGROVE). Trials, 19(1), [451]. https://doi.org/10.1186/s13063-018-2819-9

Core Outcome Set for GROwth restriction : DeVeloping Endpoints (COSGROVE). / Healy, Patricia; Gordijn, Sanne; Ganzevoort, Wessel; Beune, Irene; Baschat, Ahmet; Khalil, Asma; Kenny, Louise; Bloomfield, Frank; Daly, Mandy; Papageorghiou, Aris; Devane, Declan.

In: Trials, Vol. 19, No. 1, 451, 22.08.2018.

Research output: Contribution to journalArticle

Healy, P, Gordijn, S, Ganzevoort, W, Beune, I, Baschat, A, Khalil, A, Kenny, L, Bloomfield, F, Daly, M, Papageorghiou, A & Devane, D 2018, 'Core Outcome Set for GROwth restriction: DeVeloping Endpoints (COSGROVE)', Trials, vol. 19, no. 1, 451. https://doi.org/10.1186/s13063-018-2819-9
Healy P, Gordijn S, Ganzevoort W, Beune I, Baschat A, Khalil A et al. Core Outcome Set for GROwth restriction: DeVeloping Endpoints (COSGROVE). Trials. 2018 Aug 22;19(1). 451. https://doi.org/10.1186/s13063-018-2819-9
Healy, Patricia ; Gordijn, Sanne ; Ganzevoort, Wessel ; Beune, Irene ; Baschat, Ahmet ; Khalil, Asma ; Kenny, Louise ; Bloomfield, Frank ; Daly, Mandy ; Papageorghiou, Aris ; Devane, Declan. / Core Outcome Set for GROwth restriction : DeVeloping Endpoints (COSGROVE). In: Trials. 2018 ; Vol. 19, No. 1.
@article{09f344c79f80469f85a42cc3dd8262ba,
title = "Core Outcome Set for GROwth restriction: DeVeloping Endpoints (COSGROVE)",
abstract = "Background: Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) - one for prevention and the other for treatment of FGR. Methods: We will review the literature to identify previously reported outcomes. An international panel of relevant stakeholders who have experience of FGR (parent or carer of a baby that was growth restricted, health professional involved in the care of mothers and babies affected by FGR, a person with expertise in FGR research) will rate the importance of each of those outcomes in a series of three sequential online rounds of a Delphi study. Participants will be able to add items to the proposed list in round 1. A final face-to-face consensus meeting will be held with representatives of each stakeholder group at which a final list of outcomes for inclusion in the COS will be agreed. Discussion: The development of COSs in FGR will ensure the collection and reporting of a minimum dataset agreed by stakeholder consensus and will reduce inconsistencies in the reporting of outcomes across relevant trials. Such standardisation in the reporting of outcomes will improve synthesis of evidence and generalisability of knowledge in the future by reducing heterogeneity in outcomes between trials and thus improve the results of systematic reviews and meta-analyses. Ultimately, we hope that the COSs will lead to an improvement in the quality of evidence-based clinical practice, enhance patient care, and improve the quality and consistency of research.",
keywords = "Core outcome sets, Delphi, Foetal growth restriction, Methodology, Pregnancy",
author = "Patricia Healy and Sanne Gordijn and Wessel Ganzevoort and Irene Beune and Ahmet Baschat and Asma Khalil and Louise Kenny and Frank Bloomfield and Mandy Daly and Aris Papageorghiou and Declan Devane",
year = "2018",
month = "8",
day = "22",
doi = "10.1186/s13063-018-2819-9",
language = "English (US)",
volume = "19",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Core Outcome Set for GROwth restriction

T2 - DeVeloping Endpoints (COSGROVE)

AU - Healy, Patricia

AU - Gordijn, Sanne

AU - Ganzevoort, Wessel

AU - Beune, Irene

AU - Baschat, Ahmet

AU - Khalil, Asma

AU - Kenny, Louise

AU - Bloomfield, Frank

AU - Daly, Mandy

AU - Papageorghiou, Aris

AU - Devane, Declan

PY - 2018/8/22

Y1 - 2018/8/22

N2 - Background: Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) - one for prevention and the other for treatment of FGR. Methods: We will review the literature to identify previously reported outcomes. An international panel of relevant stakeholders who have experience of FGR (parent or carer of a baby that was growth restricted, health professional involved in the care of mothers and babies affected by FGR, a person with expertise in FGR research) will rate the importance of each of those outcomes in a series of three sequential online rounds of a Delphi study. Participants will be able to add items to the proposed list in round 1. A final face-to-face consensus meeting will be held with representatives of each stakeholder group at which a final list of outcomes for inclusion in the COS will be agreed. Discussion: The development of COSs in FGR will ensure the collection and reporting of a minimum dataset agreed by stakeholder consensus and will reduce inconsistencies in the reporting of outcomes across relevant trials. Such standardisation in the reporting of outcomes will improve synthesis of evidence and generalisability of knowledge in the future by reducing heterogeneity in outcomes between trials and thus improve the results of systematic reviews and meta-analyses. Ultimately, we hope that the COSs will lead to an improvement in the quality of evidence-based clinical practice, enhance patient care, and improve the quality and consistency of research.

AB - Background: Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) - one for prevention and the other for treatment of FGR. Methods: We will review the literature to identify previously reported outcomes. An international panel of relevant stakeholders who have experience of FGR (parent or carer of a baby that was growth restricted, health professional involved in the care of mothers and babies affected by FGR, a person with expertise in FGR research) will rate the importance of each of those outcomes in a series of three sequential online rounds of a Delphi study. Participants will be able to add items to the proposed list in round 1. A final face-to-face consensus meeting will be held with representatives of each stakeholder group at which a final list of outcomes for inclusion in the COS will be agreed. Discussion: The development of COSs in FGR will ensure the collection and reporting of a minimum dataset agreed by stakeholder consensus and will reduce inconsistencies in the reporting of outcomes across relevant trials. Such standardisation in the reporting of outcomes will improve synthesis of evidence and generalisability of knowledge in the future by reducing heterogeneity in outcomes between trials and thus improve the results of systematic reviews and meta-analyses. Ultimately, we hope that the COSs will lead to an improvement in the quality of evidence-based clinical practice, enhance patient care, and improve the quality and consistency of research.

KW - Core outcome sets

KW - Delphi

KW - Foetal growth restriction

KW - Methodology

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85052139174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052139174&partnerID=8YFLogxK

U2 - 10.1186/s13063-018-2819-9

DO - 10.1186/s13063-018-2819-9

M3 - Article

C2 - 30134949

AN - SCOPUS:85052139174

VL - 19

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 451

ER -